Policy # | Name | Purpose |
---|---|---|
1 | Harm reduction and managing substance use—Acute care [88] | To describe the organizational approach to managing substance use and implementing harm reduction interventions in the acute care setting |
2 | Philosophy of care for patients and residents who use substances [89] | To articulate a philosophy of care for people who use substances that aligns with the organization’s vision and mission |
3 | Violence prevention in the workplace [90] | To describe the organizational approach in the prevention of workplace violence, and to delineate the roles of relevant parties (e.g., leadership, staff, and occupational health and safety) |
4 | Injectable opioid agonist treatment (iOAT1) for opioid user disorder and IV fentanyl for withdrawal management [91] | To outline the protocols associated with the provision of iOAT and intravenous fentanyl |
5 | Dispensing take home naloxone kits to clients at risk of opioid overdose (adults and youth) [92] | To outline the protocol associated with the provision of take-home naloxone kits |
6 | Methadone for opioid use disorder [92] | To outline the protocol associated with the provision of methadone |
7 | Buprenorphine/naloxone (Suboxone®) for opioid use disorder [93] | To outline the protocol associated with the provision of Suboxone® |
8 | Buprenorphine/naloxone ‘(Suboxone®) to-go’ patient kits for induction outside of hospital setting [94] | To outline the protocol associated with the provision of to-go Suboxone® kits |
9 | Overdose Prevention Site (OPS) at [study site]: Operating procedures [95] | To outline operating procedures for the in-hospital OPS |